Is Descovy really the better option? [PODCAST]
“As individual patients, we often don ’t think about these costs. In my Instagram poll, nearly everyone taking Descovy reported receiving the drug effectively for free, largely due to Gilead’s copay coupons. However, as with anything in life, nothing really ever is free. More patients taking Descovy rather than generic Truvada means higher overall spending byRead more …Is Descovy really the better option? [PODCAST] originally appeared inKevinMD.com. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - February 5, 2022 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/the-podcast-by-kevinmd" rel="tag" > The Podcast by KevinMD < /a > < /span > Tags: Podcast Infectious Disease Source Type: blogs
Is Descovy really the better option?
When the FDA approved Gilead’s Truvada (emtricitabine/tenofovir disoproxil) for HIV PrEP in 2012, it was a revolutionary step forward. The drug was safe and up to 99 percent effective in preventing HIV infection in at-risk individuals. Then in 2019, Gilead received FDA approval for a second drug for PrEP called Descovy (emtricitabine/tenofovir alafenamide), with equivalentRead more …Is Descovy really the better option? originally appeared inKevinMD.com. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - December 12, 2021 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/frank-f-zhou" rel="tag" > Frank F. Zhou < /a > < /span > Tags: Meds Infectious Disease Medications Source Type: blogs
Women (still) Don ’t Get AIDS, They Just Die From It
In recent years HIV prevention
science has been revolutionized by the realization that some of the drugs
originally approved to treat HIV infection are also very effective at preventing
HIV infection in people considered at high risk, such as those with
HIV-positive partners. Known as “pre-exposure prophylaxis” or “PreP”, the HIV
medication Truvada (tenofivir plus an older antiviral called emtricitabine) is
now taken on a daily basis by millions of people worldwide in order to prevent
HIV infection. While optimists see PreP as an important step on the road to
“ending AIDS”, critics note ...
Source: blog.bioethics.net - October 21, 2019 Category: Medical Ethics Authors: Bioethics Today Tags: Health Care syndicated Source Type: blogs
PrEP prevents HIV — so why aren’t more people taking it?
Each year, 1.7 million people globally are newly infected with HIV — more than 38,000 in the United States alone. This year, President Trump announced a 10-year initiative aimed at reducing new HIV infections in the US, and ultimately ending an epidemic that has plagued this country, and the world, since HIV first emerged in the early 1980s. A key part of that plan is pre-exposure prophylaxis or PrEP, a daily medication to help prevent HIV that is recommended for people at high risk. Recently, the FDA approved a new formulation of PrEP for many — but not all — of those at risk.
What is PrEP and who should consider it...
Source: Harvard Health Blog - October 4, 2019 Category: Consumer Health News Authors: Robert Goldstein, MD, PhD Tags: Health HIV Infectious diseases Men's Health Sexual Conditions Women's Health Source Type: blogs
MKSAP: 44-year-old man with HIV, hypertension, and hyperlipidemia
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians. A 44-year-old man is evaluated in the office during a routine visit. Medical history is significant for HIV diagnosed at age 25 years, hypertension, and hyperlipidemia. He is a current smoker. Medications are chlorthalidone, tenofovir-emtricitabine, and raltegravir. On physical examination, the […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - May 18, 2019 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > < /span > Tags: Conditions Cardiology Infectious Disease Source Type: blogs
Prevention Optimism: Does It Raise Ethical Questions About PrEP for HIV?
The introduction of pre-exposure prophylaxis (PrEP) as a means of preventing HIV infections those at high risk marked a significant step in the fight against the virus. PrEP involves taking the HIV medicine Truvada or a generic version daily. It is now gradually becoming available across the world, particularly for men who have sex with… Read more
The post Prevention Optimism: Does It Raise Ethical Questions About PrEP for HIV? appeared first on The Hastings Center. (Source: blog.bioethics.net)
Source: blog.bioethics.net - January 15, 2019 Category: Medical Ethics Authors: Susan Gilbert Tags: Health Care bioethics Hastings Bioethics Forum Health and Health Care HIV PrEP prevention syndicated Source Type: blogs
MKSAP: 34-year-old man with slow-growing lesions
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 34-year-old man is evaluated for several slow-growing lesions on his penis. He first noticed the wart-like growths 3 years ago, and they have progressively enlarged. He was treated with topical cryotherapy six times and topical imiquimod over the past year without improvement; the lesions have continued to enlarge. Medical history is significant for HIV infection. Medications are tenofovir, emtricitabine, and efavirenz.
On physical examination, vital signs are normal. Multiple red to brown verrucous papules wi...
Source: Kevin, M.D. - Medical Weblog - October 20, 2018 Category: General Medicine Authors: < a href="https://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > Tags: Conditions Infectious Disease Source Type: blogs
The PrEP Paradox
By Patricia M. Davidson How in the world did we get where we are today on PrEP? I mean, the first part is easy: Through tremendous social and medical research, tireless footwork and advocacy, empathy, and interprofessional cooperation, the health care industry developed a product that could eliminate HIV in our lifetime. From a New
The post The PrEP Paradox appeared first on Johns Hopkins Nursing Magazine. (Source: Nursing Blogs at Johns Hopkins University)
Source: Nursing Blogs at Johns Hopkins University - July 30, 2018 Category: Nursing Authors: Editor Tags: Global Nursing Health Equity On the Pulse Public Health aids coinfection disparity generic drugs healthcare hiv LGBTQ medical costs PrEP Truvada Source Type: blogs
Tropical Travel Trouble 009 Humongous HIV Extravaganza
LITFL • Life in the Fast Lane Medical Blog LITFL • Life in the Fast Lane Medical Blog - Emergency medicine and critical care medical education blog
aka Tropical Travel Trouble 009
The diagnosis of HIV is no longer fatal and the term AIDS is becoming less frequent. In many countries, people with HIV are living longer than those with diabetes. This post will hopefully teach the basics of a complex disease and demystify some of the potential diseases you need to consider in those who are severely immunosuppressed. While trying to be comprehensive this post can not be exhaustive (as you can imagine any patient with a low ...
Source: Life in the Fast Lane - July 7, 2018 Category: Emergency Medicine Authors: Amanda McConnell Tags: Clinical Cases Tropical Medicine AIDS art cryptococcoma cryptococcus HIV HIV1 HIV2 PEP PrEP TB toxoplasma tuberculoma Source Type: blogs
FDA Approves Truvada as PrEP for Adolescents: Fordham University ’s Dr. Celia Fisher Weighs In
According to the U.S. Centers for Disease Control and Prevention (CDC), adolescents and young adults 13-24 comprised 21 percent of all new HIV infections in 2016, with 81 percent of those infected among young men who have sex with men (YMSM). Last week, Gilead Sciences, Inc announced that the U.S. Food and Drug Administration (FDA) […] (Source: blog.bioethics.net)
Source: blog.bioethics.net - May 30, 2018 Category: Medical Ethics Authors: Ethics and Society Tags: Ethics Health Care adolescents CDC Celia B. Fisher Celia Fisher Center for Ethics Education FDA Fordham University Center for Ethics Education Fordham University HIV and Drug Abuse Prevention Research Ethics Training Institute In the N Source Type: blogs
PrEP: Protection against HIV in a pill?
HIV (the human immunodeficiency virus) weakens the human immune system and destroys the important cells that fight disease and infection. A person can get HIV when bodily fluids — including blood, semen, pre-seminal fluid, rectal fluids, or vaginal fluids of a person with the virus — come in contact with a mucous membrane or damaged tissue. HIV can be transmitted through breast milk, or when a contaminated needle or syringe comes into direct contact with the bloodstream.
There is no cure for HIV, but with proper medical care the virus and its effects can be controlled. HIV transmission can be reduced by consistent use ...
Source: Harvard Health Blog - May 18, 2018 Category: Consumer Health News Authors: Meera Sunder, MBBS, MRCOG Tags: Health HIV Infectious diseases Source Type: blogs
Pill relief
I’m awaiting delivery of my next two weeks’ worth of medications with a major change in the blister packs. Gone will be Norvir, Prezista, Truvada and Nevirapine, all taken twice a day, and they’re being replaced with ONE pill, Genvoya, ONCE a day containing 4 new-to-me drugs in combination. What a relief, other pills continuing … Continue reading Pill relief (Source: My journey with AIDS)
Source: My journey with AIDS - December 13, 2017 Category: Infectious Diseases Authors: Kenn Tags: AIDS and HIV autobiography health-care medical update Source Type: blogs
MKSAP: 32-year-old man with a rash on his face and midchest
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 32-year-old man is evaluated for a 2-week history of a rash on his face and midchest. He describes the rash as consisting of small, reddish “lumps” that are intensely itchy; they develop and begin to resolve with development of new lesions. He otherwise feels well. Medical history is significant for a recent diagnosis of HIV infection. Medications are tenofovir, emtricitabine, efavirenz, and trimethoprim-sulfamethoxazole. On physical examination, vital signs are normal.
The patient has 1- to 3-mm papules a...
Source: Kevin, M.D. - Medical Weblog - November 11, 2017 Category: General Medicine Authors: < a href="http://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > Tags: Conditions Dermatology Infectious Disease Source Type: blogs
Memo To The President: The Pharmaceutical Monopoly Adjustment Act Of 2017
Since 1980, Congress has enacted many laws granting pharmaceutical manufacturers monopolies that no other industry enjoys. These extra monopolies were created with the expectation that monopoly profits would spur greater investment in research to find important new drugs. In fact, they have caused US consumers to pay higher prices for medicines for longer periods of time while making the pharmaceutical industry far more profitable than any other industry. I believe the next president and Congress should take several key steps, which I outline below, to roll back these costly, unnecessary monopolies.
The Current Landscape
C...
Source: Health Affairs Blog - September 13, 2016 Category: Health Management Authors: Alfred Engelberg Tags: Costs and Spending Drugs and Medical Technology Health Policy Lab Bayh-Dole Act Big Pharma Gilead Hatch-Waxman Act johnson & johnson pfizer Source Type: blogs
MKSAP: 32-year-old man with a rash on his face and midchest
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 32-year-old man is evaluated for a 2-week history of a rash on his face and midchest. He describes the rash as consisting of small, reddish “lumps” that are intensely itchy; they develop and begin to resolve with development of new lesions. He otherwise feels well.
Medical history is significant for a recent diagnosis of HIV infection. Medications are tenofovir, emtricitabine, efavirenz, and trimethoprim-sulfamethoxazole. On physical examination, vital signs are normal. The patient has 1- to 3-mm p...
Source: Kevin, M.D. - Medical Weblog - June 4, 2016 Category: Journals (General) Authors: mksap Tags: Conditions Dermatology Source Type: blogs
